Progress in Personalized Medicine Is Slower Than Some Had Expected, Partly Because of the Science and Partly Because of Insufficient Economic Incentives, Particularly for Investing in Molecular Diagnostics (MDX)
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.083
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2014
Authors
Publisher
Elsevier BV